Evidence map›Paper›PMID 35628149›Full record

ArticleInternational journal of molecular sciences2022

Comparison of Cytotoxic, Genotoxic, and DNA-Protective Effects of Skyrin on Cancerous vs. Non-Cancerous Human Cells.

Terézia Zajičková, Eva Horváthová, Stanislav Kyzek, Eva Šályová, Eva Túryová, Andrea Ševčovičová, Eliška Gálová

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Terézia ZajičkováDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.ORCID 0000-0002-5528-3939
Eva HorváthováCancer Research Institute, Biomedical Research Centre of the Slovak Academy of Sciences, Dúbravská Cesta 9, 845 05 Bratislava, Slovakia.
Stanislav KyzekDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.ORCID 0000-0001-8841-4002
Eva ŠályováDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.
Eva TúryováDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.
Andrea ŠevčovičováDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.ORCID 0000-0003-2912-5184
Eliška GálováDepartment of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.
Comenius University Bratislava · SKSlovak Academy of Sciences · SK

Funding

Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA 1/0460/21Slovak Research and Development Agency APVV-18-0125
6 · The paper itself

Abstract

Secondary metabolites as a potential source of anticancer therapeutics have been the subject of many studies. Since hypericin, a metabolite isolated from

Indexed as

Antineoplastic AgentsDNA DamageAnthraquinonesDNAHumansAnthraquinonesAntineoplastic AgentsDNAskyrincomet assaycytotoxicityDNA-protectivitygenotoxicityHepG2 cellslymphocytesskyrin

Identifiers

PMID35628149
PMCPMC9142076
OpenAlexW4280525170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.